Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.94 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.94 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.94 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartocin SCHEMBL2398841 | 1.00 | OXTR (0.94) | OXTRAVPR1AAVPR1BAVPR2 | |
| Aspartocin SCHEMBL193132 | 1.00 | OXTR (0.94) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL19712185 | 0.98 | OXTR (0.90) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL122621 | 0.98 | OXTR (0.90) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL29048 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL20707334 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15512173 | 0.97 | OXTR (0.92) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL21527573 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL1173243 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 | |
| Oxytocin SCHEMBL16373316 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR1BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115634080-A | Bone material dispensing system and method of use | 华沙整形外科股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-109010916-B | Moldable formulations containing oxysterol in acellular tissue matrices | 华沙整形外科股份有限公司 | 2022-03-04 | — | — | CN | disclosed |